Matrixyl: the complete guide.

Matrixyl is a cosmetic peptide. It's been in commercial skincare for two decades. The biology is real. Published clinical studies have reported modest wrinkle-depth improvements at 12 weeks.

What is Matrixyl, structurally?

Matrixyl is the cosmetic-industry name for palmitoyl pentapeptide-4, also written as Pal-KTTKS. The "pentapeptide" part is a five-amino-acid string: Lys-Thr-Thr-Lys-Ser (KTTKS). That sequence is a fragment of type-I procollagen, the precursor used to build collagen.

KTTKS on its own is water-loving and cannot cross the stratum corneum. Sederma conjugated it to a 16-carbon saturated fatty acid (palmitic acid), providing a lipid anchor that facilitates transdermal penetration to the dermis.

The Sederma product line uses naming that is frequently confused in the literature and commercial descriptions. The key distinctions are:

• Matrixyl equals palmitoyl pentapeptide-4 equals Pal-KTTKS. One peptide.
• Matrixyl 3000 is palmitoyl tripeptide-1 plus palmitoyl tetrapeptide-7. Different molecules. Different mechanism (matrikine signaling, not collagen stimulation).
• Matrixyl synthe'6 is palmitoyl tripeptide-38. A third Sederma product targeting six structural matrix proteins.

The names share a stem because Sederma made all three. The molecules are not similar. The original Matrixyl is the one with the deepest data, and it's the simple Pal-KTTKS introduced in the early 2000s.

How does Matrixyl work in skin?

The mechanistic foundation dates to 1993. Katayama and colleagues demonstrated that the KTTKS fragment stimulates fibroblasts — the dermal cells responsible for collagen synthesis — in vitro. KTTKS is released during normal procollagen processing and appears to function as a feedback signal for further extracellular matrix production.

This is the molecular rationale underlying Matrixyl. If KTTKS stimulates fibroblast collagen production in culture, and topical delivery can transport it to the dermis, the hypothesis is that it may attenuate the collagen loss associated with photoaging.

Bare KTTKS can't reach the dermis on its own. The palmitoyl tail solves that. Skin permeation studies confirm real transdermal delivery. But the amount reaching the dermis is small. That's a big reason the clinical effects are also small.

What does the clinical evidence actually show?

The pivotal trial is Robinson et al., 2005. Twelve weeks, double-blind, placebo-controlled. 93 women with photoaged facial skin (Robinson 2005) applied Pal-KTTKS or vehicle twice daily.

Researchers measured outcomes at 4, 8, and 12 weeks. They used three methods: expert visual scoring, photo analysis, and silicone replicas of the skin's micro-topography. Improvements showed up at 8 weeks and held at 12.

The key reported outcome: 15–20% reduction in wrinkle depth (vs placebo, 2005). The effect is measurable under controlled conditions, though described as modest relative to retinoid comparators. A separate JAAD trial of a palmitoyl-pentapeptide moisturizer reported similar directional results.

Matrixyl — not yet stocked

Pal-KTTKS 5 aa + palmitoyl Procollagen fragment

Matrixyl is on the Peptriva roadmap. Our currently stocked cosmetic peptide is GHK-Cu — the topical-skincare cornerstone with the deepest RCT base in this category, including the studies cited across this guide for context. See the cosmetic peptides overview for the full category map.

View GHK-Cu

Matrixyl vs Matrixyl 3000: which is which?

• Matrixyl (original) is palmitoyl pentapeptide-4 (Pal-KTTKS). One peptide. It stimulates collagen synthesis through the procollagen feedback pathway Katayama discovered in 1993.
• Matrixyl 3000 is palmitoyl tripeptide-1 plus palmitoyl tetrapeptide-7. Two peptides. Mechanism is matrikine signaling, which mimics fragments the skin releases during repair and remodeling.
• The marketing problem: Matrixyl 3000 sometimes gets pitched as a "third generation" upgrade. It isn't. It's a different product on a different pathway. Independent clinical evidence is thinner. Most public data comes from Sederma's own brochures, not peer-reviewed trials.

Matrixyl concentration in finished cosmetic formulations

Matrixyl ships to cosmetic manufacturers as a raw-material solution containing 500 ppm (0.05%) Pal-KTTKS. Finished serums typically incorporate that solution at 3–8% of formula weight. The resulting peptide concentration in a finished product is therefore approximately 15–40 ppm (0.0015–0.004%).

For comparison, GHK-Cu sits at 0.1–0.4% (100–400x the Matrixyl mass) in the most-cited topical trials. Matrixyl is stable at pH 5.5 to 7, is compatible with retinoids in formulation, and has a reported 24-month shelf-life. Liposomal delivery has shown improved dermal permeation in in-vitro studies, though most commercial formulations do not employ this approach.

How does Matrixyl compare to the alternatives?

1. Matrixyl vs retinoids

Retinoids demonstrate greater efficacy on published effect-size measures. Tretinoin, retinol, retinaldehyde, and adapalene have 40+ RCTs in photoaging. Prescription tretinoin carries FDA approval. The reported trade-off is tolerability: retinoids are associated with peeling, irritation, photosensitivity, and restrictions during pregnancy.

Matrixyl has been reported to produce smaller effects with a milder tolerability profile. Research contexts where retinoid tolerability is a limiting variable have explored Matrixyl as an adjunct ingredient.

2. Matrixyl vs GHK-Cu

Among cosmetic peptides, GHK-Cu has a deeper RCT base. It's been studied for collagen synthesis, hair follicle activity, wound healing, and a documented ~4,000-gene transcriptomic signature (fibroblasts). Pickart first characterized it in 1973. That gives it a mechanistic anchor most cosmetic peptides lack. Matrixyl's pathway is cleaner. GHK-Cu's application range is wider. Both effects are modest.

3. Matrixyl vs Argireline

Argireline (acetyl hexapeptide-8) targets dynamic expression lines through a weak topical mechanism that mimics how botulinum toxin works. Matrixyl targets lines from collagen loss. They go after different wrinkles. Argireline's clinical data is sparse and mostly manufacturer-sponsored. Matrixyl has the cleaner story and better-documented effects.

Is Matrixyl safe?

Two decades of commercial use are associated with a low documented adverse-event profile. The peptide is not considered to be absorbed systemically in meaningful amounts. Palmitic acid is a normal skin lipid. KTTKS is a fragment of a human structural protein. Both the Cosmetic Ingredient Review and EU SCCS reviewed the ingredient without flagging safety concerns at typical concentrations.

• Commonly reported: no adverse events specific to the peptide itself. Mild irritation reported in commercial use is generally attributed to other formulation components.
• Allergic contact dermatitis: rare in the published literature.
• Pregnancy and breastfeeding: no specific contraindication identified; dedicated exposure data are limited.
• Photosensitivity: none documented. Unlike retinoids, Matrixyl has not been associated with increased UV sensitivity.

What's the regulatory status?

Matrixyl is regulated as a cosmetic ingredient, not a drug. In the U.S. it sits under FDA's cosmetic framework. No premarket approval is required, but manufacturers can't make disease-treatment claims. The EU regulates it under Cosmetics Regulation EC 1223/2009.

Sederma owns the trade name. The underlying molecule (palmitoyl pentapeptide-4) is generic. Other formulators list it under its INCI name when they're not buying from Sederma. One important caveat: Matrixyl isn't an injectable. If a vendor is offering injectable Matrixyl, they're working outside the molecule's documented use envelope.

Our stocked cosmetic peptide: GHK-Cu

Tripeptide-1 ≥99% pure Lyophilized

Matrixyl is on our roadmap but not yet stocked. The cosmetic peptide we do carry is GHK-Cu — the most extensively researched topical cosmetic peptide in the catalog, with documented effects on collagen synthesis, hair-follicle stimulation, and wound healing. COA available with every lot. See the cosmetic peptides overview for the full picture.

Learn more about GHK-Cu

Frequently asked questions

What is Matrixyl?

Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), developed by Sederma. The KTTKS procollagen fragment is conjugated to palmitic acid to facilitate transdermal penetration. It is marketed as a topical collagen-stimulating cosmetic ingredient.

Matrixyl vs Matrixyl 3000?

Original Matrixyl is one peptide (palmitoyl pentapeptide-4). Matrixyl 3000 is a different Sederma combination (palmitoyl tripeptide-1 plus palmitoyl tetrapeptide-7) on a different pathway. The independent clinical evidence is deeper for the original.

Matrixyl vs Argireline?

Both are cosmetic peptides on different mechanisms. Matrixyl works on collagen-loss wrinkles. Argireline (acetyl hexapeptide-8) is sold for dynamic expression lines through a weak topical mechanism. Different wrinkles. They're sometimes combined.

Does Matrixyl actually build collagen?

In fibroblast cell culture, the parent KTTKS pentapeptide has been shown to stimulate collagen and glycosaminoglycan synthesis (Katayama et al., 1993). Whether topical application produces clinically meaningful collagen-density changes in vivo is less well established. The Robinson 2005 trial reported modest improvements in wrinkle depth, with smaller effect sizes than retinoid comparators in the literature.

How long do clinical studies show Matrixyl takes to produce measurable effects?

The pivotal Robinson et al. 2005 trial measured outcomes at 4, 8, and 12 weeks of twice-daily topical application. Statistically significant improvements in wrinkle depth and density were observed at 8 weeks and maintained at 12. The trial data indicate 8–12 weeks of consistent application before measurable changes appeared in study participants. Effects required continued application to be maintained.

Matrixyl vs retinoid — what does the evidence show?

Retinoids (tretinoin, retinol, retinaldehyde) have larger published evidence bases and larger reported effect sizes in photoaging studies. Tretinoin carries FDA approval and decades of Phase III data. Studies have reported that Matrixyl produces real but modest effects with a milder tolerability profile — lower rates of peeling, photosensitivity, and no documented pregnancy contraindication. The literature positions it as an adjunct ingredient rather than a retinoid equivalent.

Is Matrixyl safe?

Two decades of commercial topical use are associated with a low adverse-event profile. Systemic absorption is not considered clinically meaningful at typical formulation concentrations. Both the Cosmetic Ingredient Review (CIR) and the EU SCCS have reviewed the ingredient and did not identify safety concerns at standard use levels. It is a topical cosmetic ingredient; injectable use falls outside the documented use envelope.